Inclusion Criteria:

          -  Expected to survive more than 3 months

          -  PS 0-2

          -  Immunohistochemistry was confirmed to be GPC3 positive hepatocellular carcinoma

          -  Patients with no ability to receive TACE combined with sorafenib

          -  WBC>3.5×1e+9/L,Hb>90g/L,PLT>75×1e+9/L

          -  HBV DNA copy number less than 100/ml

          -  ALT≤5ULN, AST≤5ULN, TB≤1.5ULN, ALB≥35g/L

          -  Understand this test and have signed informed consent

        Exclusion Criteria:

          -  Hepatic encephalopathy, autoimmune diseases, or any uncontrolled active disease that
             hinders participation in the trial

          -  Decompensated liver cirrhosis, liver function Child-pugh C grade

          -  Portal vein tumor thrombus, arterial portal fistula, hepatic arteriovenous

          -  Long-term use of immunosuppressive agents after organ transplantation

          -  Screening indicated that the target cell transfection rate was less than 30%

          -  Invasive pulmonary embolism, deep venous thrombosis, or other major arterial / venous
             thromboembolic events occurred 30 days or 30 days prior to randomization

          -  Subjects had an active or uncontrollable infection requiring systemic therapy 14 days
             or 14 days prior to randomization

          -  Pregnant or lactating subjects

          -  In the opinion of the investigator, the presence of a medical history or a history of
             mental state may increase the number of subjects associated with the risk factors
             associated with the study or study drug administration

          -  Subjects who have signed a written consent or who are in compliance with the study
             procedure; or who are unwilling or unable to comply with the study